Report Finds Reproductive Medicine Associates of New Jersey’s 2012 IVF Success Rates to be 23 Percent Above National Average for Women Under 35

February 18, 2014

RMANJ IVF Success Driven by its Pioneering Research, Proprietary Genetic Screening, Extended Culture, Comprehensive Chromosome Screening, Endometrial Synchrony and Single Embryo Transfer

BASKING RIDGE, N.J., Feb. 18, 2014 /PRNewswire/ — Reproductive Medicine Associates of New Jersey (RMANJ) has released in-vitro fertilization (IVF) success rates for the year ending December 2012, the most recent data reported yesterday by The Society of Assisted Reproductive Technology (SART). The data highlighted that RMANJ continues to generate some of the highest IVF delivery rates in the US.

RMANJ, a world-renowned leader in the field of Assisted Reproductive Technology (ART), attributes their success rates to its cutting-edge research, patient centered approach, and unwavering commitment to helping hopeful parents deliver healthy babies.

“While our current approach to IVF has dramatically increased success rates, we know there is more research to be done,” said Dr. Richard T. Scott Jr., a founding partner of RMANJ. “We are dedicated to pioneering new approaches to increase the likelihood of implantation and increased birth rate while ensuring a healthier delivery.”

Through extensive research, RMANJ has found that a process that includes SelectCCS (Comprehensive Chromosome Screening), endometrial synchrony and Single Embryo Transfer (SET) continues to produce the highest success rates for their patients.(1) RMANJ’s focus on endometrial synchrony results in freezing more embryos to maximize the window of implantation for each patient.

When compared to the national average, RMANJ continues to deliver higher success rates across all age groups and maintains a lower number of embryos transferred per cycle.

Thawed Embryos From Non-Donor Oocytes (Non-Donor Eggs)

                                                Thawed Embryos From Non-Donor Oocytes (Non-Donor Eggs)

              Age Group  <35       35-37       38-40           41-42            >42


                        RMANJ       Nat        RMANJ          Nat Avg          RMANJ          Nat Avg     RMANJ      Nat Avg     RMANJ      Nat Avg


    # of
     transfers                486      15,667        287           7,884             242           5,657         98        2295         32       1,532


    % of
     resulting in
     live births             65.0%       42.2%      58.2%           39.8%           51.2%           33.9%      36.7%       26.4%        25%       17.8%
    -------------            ----        ----       ----            ----            ----            ----       ----        ----        ---        ----

    Avg number of
     transferred              1.6         1.8        1.4             1.8             1.5             1.8        1.4         1.9        1.3         2.0
    -------------             ---         ---        ---             ---             ---             ---        ---         ---        ---         ---

“When looking at the SART report, patients should also look at multiple pregnancy rates in addition to delivery rates for their age group. When we’re talking about getting a patient pregnant, we are ideally looking for a singleton pregnancy, the lowest-risk situation for mother and child, “offered Dr. Michael R. Drews, a founding partner of RMANJ. “Our holistic approach to IVF focuses on finding new ways to achieve the highest delivery rates while concentrating on the most viable and healthy solutions for our patients and their babies” added Dr. Drews.

As required by the Fertility Clinic Success Rate and Certification Act of 1992, reproductive endocrinologists must report in-vitro fertilization (IVF) delivery rates to the Centers for Disease Control (CDC) and The Society of Assisted Reproductive Technology (SART), the primary organization of professionals dedicated to the practice of Assisted Reproductive Technologies in the United States. RMANJ’s full Clinic Summary Report can be viewed at http://www.sart.org/find_frm.html.

About SART
The Society for Assisted Reproductive Technology, or SART, is the primary organization of professionals dedicated to the practice of assisted reproductive technologies (ART) in the United States. SART includes more than 375 member practices, representing more than 85 percent of the ART clinics in our country. The mission of the organization is to set and help maintain the standards for ART in an effort to better serve its members and patients. One of the most important functions of the SART website is to help patients locate and contact infertility clinics and view national and individual clinic IVF success rates.

Please note, a comparison of clinic success rates may not be meaningful because a patient’s medical characteristics, treatment approaches and entrance criteria for ART may vary from clinic to clinic.

About Reproductive Medicine Associates of New Jersey
Reproductive Medicine Associates of New Jersey have pioneered and successfully implemented a cutting-edge technology, known as Comprehensive Chromosome Screening (CCS). Other centers have attempted similar testing methods, however RMANJ is one of the foremost fertility centers in the world to have developed a system of unprecedented accuracy and validated through years of rigorous clinical research. RMANJ’s Comprehensive Chromosome Screening offers advanced embryo selection with extreme accuracy by detecting and avoiding use of embryos with chromosomal abnormalities prior to transfer.

The fertility experts at RMANJ have among the highest IVF success rates in the country. Since 1999, they have helped bring more than 30,000 babies to loving families. In addition to serving as the Division of Reproductive Endocrinology at Rutgers Robert Wood Johnson University Medical School in New Brunswick, NJ, the practice has seven locations in New Jersey. For more information please call RMANJ at 973-656-2089, or visit www.rmanj.com.

(1) Forman EJ, Hong KH, Ferry KM et al. In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial. Fertil Steril 2013.

SOURCE Reproductive Medicine Associates of New Jersey

Source: PR Newswire

comments powered by Disqus